Carmat on December 3 said the French medical device company suspended implants of the Aeson artificial hearts following a quality issue affecting some of its prostheses.
If you are not happy with the results below please do another search
50 search results for:
A sixth U.S. state – Nebraska – reported the Omicron variant of the coronavirus after detecting six confirmed cases of the highly contagious strain, the state’s health department said on December 3.
Scientists believe they have found the likely cause of blood clotting in some recipients of the Oxford-AstraZeneca Covid-19 vaccine.
The U.S. Securities and Exchange Commission filed insider trading charges against Usama Malik, the former chief financial officer of Immunomedics Inc.
BioSpace reviewed some of the more interesting scientific studies recently published, including research into a potential cause of Alzheimer’s disease and how deleting dysfunctional fat cells could alleviate diabetes.
BioNTech should be able to adapt the German company’s coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, CEO Ugur Sahin told the Reuters Next conference on December 3.
The World Health Organization’s chief scientist told the Reuters Next conference on December 3 the Omicron variant could become dominant because it is highly transmissible, but that a different vaccine may not be needed.
New York confirmed five cases of the Omicron coronavirus variant – the NY governor said on December 2 – bringing to five the number of U.S. states having detected the variant, with 10 reported infections nationwide.
The likelihood that people will need to have an annual Covid-19 vaccine – similar to the influenza shot – is increasing, BioNTech chief executive and co-founder Ugur Sahin told the Reuters Next conference on December 3.
Swiss drug giant Novartis and Belgian pharma company UCB announced a deal to co-develop and commercialize two products targeting Parkinson’s disease, UCB0599 and UCB7853.